Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares
Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G/A, reporting a beneficial ownership of 3,436,000 shares of Voyager Therapeutics, Inc. (VYGR) common stock, which represents 5.58% of the class. They hold shared voting and dispositive power over these shares, which are directly held by Armistice Capital Master Fund Ltd. This filing indicates a moderate impact and neutral sentiment.
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%
Analysts have significantly cut their revenue estimates for Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 47% for the current year, now projecting US$21 million for 2026, a 40% decline from the previous year. The revised forecast also anticipates a slight increase in loss per share to US$1.68. This negative revision is noteworthy as the company's revenue is expected to decline faster than the overall industry, leading to increased caution among investors.
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%
Analysts have significantly revised down their revenue estimates for Voyager Therapeutics, Inc. (NASDAQ:VYGR) for 2026 by 47%, now expecting US$21 million, a 40% decline from the previous year. Concurrently, loss per share estimates have increased. This downgrade reflects a more conservative outlook for the company's financial performance, forecasting a faster decline in sales compared to the broader industry.
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%
Analysts have significantly revised down their revenue forecasts for Voyager Therapeutics (NASDAQ:VYGR) by 47% for 2026, now expecting US$21m, a 40% decline from last year. The consensus also anticipates a slight increase in loss per share to US$1.68. This downgrade suggests a more conservative outlook from analysts, with the company's sales growth expected to underperform the broader industry.
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright
HC Wainwright reaffirmed its "Buy" rating for Voyager Therapeutics (NASDAQ:VYGR), contributing to a "Moderate Buy" consensus and a $16.50 price target from analysts. The company reported adjusted quarterly losses of $0.40 per share, surpassing estimates, but revenue of $3.17 million fell short of expectations. Institutional investors own 48.03% of the outstanding shares, with the stock opening at $3.27 and a market capitalization of approximately $197.6 million.
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Voyager Therapeutics (NASDAQ:VYGR) recently released its second-quarter results, leading to a 7.9% increase in share price. While revenues were lower than analyst predictions, losses per share were also smaller than expected. Analysts have updated their forecasts, increasing revenue estimates for 2026 but also raising loss per share projections due to anticipated growth costs.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Voyager Therapeutics recently released its second-quarter results, and analysts have updated their forecasts for the company's performance this year and beyond. The consensus earnings per share estimates for 2026 have been significantly reduced, although revenue projections remain largely stable. Despite a challenging outlook, analysts generally maintain a "buy" rating for the stock, indicating confidence in its long-term potential.
Voyager Therapeutics, Inc. Q2 2026: Revenue $3.2M, Net loss $24.5M — 10-Q Summary
Voyager Therapeutics, Inc. reported its Q2 2026 financial results, with revenues of $3.2M and a net loss of $24.5M, showing an improvement in net loss year-over-year despite a decline in revenue. The company highlighted clinical progress with IND clearance for VY1706 and completed enrollment for VY7523 Phase 1 MAD, along with a strong financial runway into 2028 supported by reduced expenses and significant non-dilutive funding from partnerships.
Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist
Voyager Therapeutics (VYGR) stock saw a 4.5% rebound despite reporting another quarterly loss, with basic EPS at US$0.40 in the red. The company's revenue declined to US$3.17 million from US$5.20 million in the prior year, though net losses narrowed. While clinical milestones like FDA IND clearance for VY1706 offer some bullish sentiment, concerns about cash burn and a concentrated pipeline persist for investors.
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates
Voyager Therapeutics Inc (NASDAQ: VYGR) reported second-quarter earnings per share (EPS) of $-0.400, surpassing the analyst estimate by $0.10. However, the company's revenue for the quarter was $3.17 million, falling short of the consensus estimate of $4.74 million. The stock price has seen a decline of -22.720% in the last three months and -2.800% in the last 12 months.
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8
Wedbush has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained a target price of $8. This indicates continued confidence in the company's performance and future prospects from the investment firm.
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) reported a Q2 loss of $0.4 per share, surpassing the Zacks Consensus Estimate of a $0.55 loss. However, the company missed revenue estimates, posting $3.17 million against an expectation of $3.49 million. Despite outperforming EPS estimates in the last four quarters, its shares have declined by 21.1% year-to-date, contrasting with the S&P 500's gain.
VOYAGER THERAPEUTICS Q2 COLLABORATION REVENUE USD 3.165 MILLION
Voyager Therapeutics reported collaboration revenue of $3.165 million for the second quarter. This financial update provides key insight into the company's performance during this period, specifically highlighting revenue generated through its collaborative efforts.
Voyager Reports Second Quarter 2026 Financial and Operating Results
Voyager Therapeutics, Inc. reported its second-quarter 2026 financial and operating results, highlighting progress in its Alzheimer's disease programs, VY7523 and VY1706, both expected to reach clinical milestones in Q4 2026. The company ended the quarter with $149 million in cash, providing a runway into 2028. Financials showed a decreased net loss and reduced R&D and G&A expenses compared to the previous year.
VYGR Looks 86.3% Overvalued on GF Value™
Voyager Therapeutics Inc (NASDAQ: VYGR) missed revenue expectations in Q2 2026, reporting $3.17 million against an anticipated $4.56 million, and is focusing on tau-targeted Alzheimer's therapies. Despite its current stock price of $3.13, its GF Value™ suggests it is 86.3% overvalued at $1.68, reflecting a mixed financial profile with moderate financial strength but weak profitability. While two premium gurus have added VYGR shares, insider selling totaling $405,470 has occurred in the past year, indicating differing views on its near-term valuation.
Voyager Therapeutics reports Q2 2026 net loss $24.5M, cash $148.8M; runway into 2028
Voyager Therapeutics reported a Q2 2026 net loss of $24.5 million on collaboration revenue of $3.2 million, ending the period with $148.8 million in cash, cash equivalents, and marketable securities. The company anticipates this liquidity, combined with expected collaboration reimbursements and interest, will fund operations into 2028. Voyager also highlighted upcoming clinical milestones in Q4 2026 for its two Alzheimer’s programs, VY7523 and VY1706.
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates
Voyager Therapeutics Inc (NASDAQ: VYGR) reported a second-quarter EPS of $-0.400, surpassing analyst estimates by $0.10. However, the company's revenue of $3.17M fell short of the consensus estimate of $4.74M. The stock has seen a decline of -22.720% in the last three months and -2.800% in the last 12 months.
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates
Voyager Therapeutics Inc (NASDAQ: VYGR) reported its second-quarter earnings, beating analyst estimates for EPS by $0.10 with $-0.400, but falling short on revenue at $3.17 million against an expected $4.74 million. The company's stock has seen a decline of -22.720% over the last three months and -2.800% over the last year. InvestingPro rates Voyager Therapeutics Inc's financial health as "fair performance."
Voyager Therapeutics: Q2 Earnings Snapshot
Voyager Therapeutics Inc. (VYGR) reported a Q2 loss of $24.5 million, or 40 cents per share, which exceeded Wall Street expectations for a loss of 55 cents per share. However, the gene therapy company's revenue of $3.2 million fell short of the $3.5 million forecasted by analysts. This financial snapshot was generated using data from Zacks Investment Research.
Voyager Reports Second Quarter 2026 Financial and Operating Results
Voyager Therapeutics, Inc. reported its second quarter 2026 financial and operating results, highlighting progress in its Alzheimer's disease programs, VY7523 and VY1706, with clinical data and trial initiation expected in Q4 2026. The company ended the quarter with $149 million in cash, providing a runway into 2028. Financial results showed decreased collaboration revenue, R&D expenses, and G&A expenses compared to Q2 2025, leading to a reduced net loss.
Voyager Therapeutics (VYGR): Millennium entities disclose 7.4% beneficial stake in Schedule 13G/A
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have disclosed a beneficial ownership of 7.4% in Voyager Therapeutics (VYGR) common stock through a Schedule 13G/A filing. Integrated Core Strategies (US) LLC also reported a 7.3% stake. The filing clarifies that while these entities hold shared voting and dispositive power over the shares, the disclosure itself should not be construed as an admission of beneficial ownership by Millennium Management, Millennium Group Management, or Mr. Englander.
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Voyager Therapeutics Inc is projected to report a loss of 48 cents per share in its upcoming earnings. This information is provided as an earnings preview from Refinitiv via Reuters. The full article content is accessible on TradingView.
Voyager Therapeutics Inc (VYGR) Institutional Confidence
Voyager Therapeutics Inc (VYGR) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 65.36%, marking an 18.22% quarter-over-quarter increase. Key institutional shareholders include Neurocrine Biosciences Inc, EcoR1 Capital, LLC, and Armistice Capital LLC.
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Voyager Therapeutics Inc (VYGR), outlining major shareholders and institutional holdings. It provides a breakdown of proportional ownership by various entity types and tracks changes in institutional shareholding and individual shareholder activity over recent quarters. The data indicates Neurocrine Biosciences Inc. as the largest shareholder and lists several other significant institutional investors.
Voyager Therapeutics Inc (VYGR) Cash Flow
This article provides a detailed cash flow statement for Voyager Therapeutics Inc (VYGR), covering quarterly and annual data for operating, investing, and financing activities. It presents historical financial figures and year-over-year changes for various cash flow components. Additionally, the article includes an FAQ section explaining key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow, along with Voyager Therapeutics Inc's performance in these areas.
TradingKey
This article provides a detailed quarterly and annual income statement for Voyager Therapeutics Inc. (VYGR), covering financial performance metrics such as total revenue, operating expenses, net income, and earnings per share from FY2014Q1 to FY2026Q1. It also includes FAQs explaining how to interpret the income statement and key financial terms. The data helps investors analyze the company's operational efficiency and profitability over time.
Voyager Therapeutics Inc (VYGR) Financial Health: Profitability & Balance Sheet Analysis
Voyager Therapeutics Inc (VYGR) has a current financial score of 5.98, placing it 303rd out of 386 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company's latest quarterly revenue was $2.59 million, a 59.94% year-over-year decrease, while net profit decreased by 9.94% year-over-year. Key data for quality of earnings, operational efficiency, growth potential, and shareholder returns have not been disclosed by the company.
Voyager Therapeutics, Inc. Revenue Breakdown – NASDAQ:VYGR
Voyager Therapeutics, Inc. (NASDAQ: VYGR) generated $40.37 million in revenue last year, with its Genetic Medicine segment being the sole contributor. This marked a decrease from $80.00 million reported in the previous year. The United States was the primary source of revenue for the company for both years.
H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data
H.C. Wainwright has reiterated its Buy rating and a $25.00 price target for Voyager Therapeutics (NASDAQ: VYGR) after reviewing updated preclinical data for the company's tau-silencing gene therapy program, VY1706. The data showed significant and sustained tau reduction in non-human primates, supporting the FDA's clearance of an Investigational New Drug application for VY1706. Voyager Therapeutics plans to initiate a clinical trial for VY1706 in adults with early Alzheimer's disease in the second half of 2026.
H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data
H.C. Wainwright has reiterated a Buy rating and a $25.00 price target for Voyager Therapeutics (NASDAQ:VYGR) following positive updated preclinical data from its tau-silencing gene therapy program, VY1706. The data showed sustained tau reduction in non-human primates and supported the FDA's clearance of an investigational new drug application for VY1706. The company plans to initiate a clinical trial in adults with early Alzheimer’s disease in the second half of 2026.
Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early
Voyager Therapeutics' stock price dropped 10% recently, impacting insiders who sold shares over the past year. While insiders sold US$405k worth of stock at an average price of US$3.79, which is higher than the current US$3.24, they may have sold too early. The article notes a lack of recent insider buying and low insider ownership, suggesting potential risks, but emphasizes that this analysis is not financial advice.
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8
Wedbush has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained its target price at $8. This indicates the firm's continued confidence in the company's financial performance or future prospects.
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12
CCORF has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained a target price of $12. This indicates a continued positive outlook on the company's stock performance from the analyst.
Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early
Voyager Therapeutics' stock has recently dropped 10%, yet insiders who sold US$405k worth of stock over the past year might have sold too early, as their average selling price of US$3.79 is still below the current share price of US$3.24. Although insider selling occurred at a price higher than the current market value, there have been no insider buys, and insiders currently hold about 1.2% of the stock. Investors are advised to consider potential risks and look for significant insider buying.
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics announced positive six-month GLP toxicology data for its investigational gene therapy VY1706, showing it was well-tolerated and reduced tau protein by up to 75% in non-human primates after a single intravenous dose. The company received FDA IND clearance for VY1706 in June, and plans to initiate a clinical trial in adults with early Alzheimer's disease in the second half of 2026, targeting tau as a potentially transformative treatment for the condition. The data presented at AAIC 2026 reinforces the compelling pharmacology and safety profile observed to date.
Voyager reports VY1706 Alzheimer’s therapy data
Voyager Therapeutics reported positive six-month toxicology results for its investigational Alzheimer’s gene therapy, VY1706, showing significant reductions in tau protein levels in non-human primates. The therapy was well-tolerated, and the FDA has cleared Voyager's IND application, allowing the company to begin human clinical trials in early Alzheimer’s patients during the second half of 2026. This advancement targets the tau protein, a key factor in Alzheimer's progression, utilizing Voyager’s gene therapy platform.
Voyager presents six-month data for Alzheimer’s gene therapy
Voyager Therapeutics Inc. presented positive six-month toxicology data for its investigational gene therapy VY1706 for Alzheimer's disease at a conference in London. The data showed that VY1706 significantly reduced tau protein in non-human primates and was well tolerated. The company received FDA clearance for VY1706 in June and plans to begin human trials in the latter half of 2026.
Single-dose Alzheimer’s gene therapy from Voyager lowers brain tau in primates
Voyager Therapeutics reported positive 6-month GLP toxicology results for its investigational Alzheimer’s gene therapy, VY1706. The single intravenous dose was well tolerated in non-human primates and significantly reduced tau protein by up to 75% in key brain regions. The company received FDA IND clearance in June, and plans to initiate a clinical trial for adults with early Alzheimer's disease in the second half of 2026.
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics presented positive six-month toxicology data for VY1706, their investigational gene therapy for Alzheimer's disease, at AAIC 2026. The therapy was well-tolerated and significantly reduced tau protein in non-human primates. Following recent FDA IND clearance, Voyager aims to initiate clinical trials in adults with early AD in the second half of 2026.
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics announced positive six-month GLP toxicology data for its investigational gene therapy VY1706, designed to treat Alzheimer’s disease. The study showed that a single intravenous dose of VY1706 was well tolerated and significantly reduced tau protein by up to 75% in non-human primates. Following FDA IND clearance, Voyager expects to begin clinical trials in adults with early Alzheimer's disease in the second half of 2026.
Voyager Therapeutics (VYGR) Short Interest & Short Float | Updated Jul 2026
As of June 30, 2026, Voyager Therapeutics (VYGR) had a short interest of 3.57 million shares, which is 6.78% of its public float, marking a 1.99% decrease from the previous report. The short interest ratio is 5.1 days to cover. The article provides detailed historical short interest data and defines key metrics like shares sold short, short float, and days to cover, indicating a slightly bearish to neutral sentiment among investors regarding VYGR.
Voyager Therapeutics outlines gene therapy pipeline. Clinical partnerships frame the next phase
Voyager Therapeutics, a clinical-stage biotechnology company, is focused on developing gene therapies for serious neurological diseases, particularly targeting conditions of the central nervous system using AAV-based therapies. The company employs a business model that combines internal research with collaborations with larger pharmaceutical partners to spread development risks and access commercial infrastructure. Their pipeline includes programs for movement disorders like Parkinson's disease, aiming for durable clinical benefits from single administrations.
Voyager Therapeutics outlines its gene therapy pipeline. Investors focus on neurology targets
Voyager Therapeutics is advancing a neurology-focused gene therapy pipeline, utilizing its CNS delivery technology to develop treatments for severe neurological conditions. The company's strategy involves both internal development and collaborations with larger pharmaceutical partners, with a focus on progressing therapeutic candidates through clinical trials and toward commercialization. Investors are closely monitoring the success of its partnerships and the clinical outcomes of its gene therapy programs in the competitive biotechnology sector.
VYGR - Voyager Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Voyager Therapeutics Inc (VYGR). It includes detailed financial metrics such as market capitalization, income, sales, P/E ratios, employee count, and stock performance data. The report also highlights insider and institutional ownership, analyst recommendations, and key valuation ratios.
Voyager Therapeutics : VYGR
This article provides an overview of Voyager Therapeutics Inc (VYGR), a biotechnology firm specializing in gene therapies for neurological diseases like Alzheimer's. It highlights the company's leading project, VY-TAU01, and its collaborations with partners such as Alexion and Novartis. The text also includes stock data for VYGR and mentions an article discussing Jim Cramer's advice on the stock.
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
This article provides the enterprise value to revenue forward for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It confirms that the financial data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to be a financial data point from TradingView.
Price to book forward of Voyager Therapeutics, Inc. – FWB:VT6
This article provides the "Price to book forward" financial metric for Voyager Therapeutics, Inc., traded on the Frankfurt Stock Exchange under the ticker FWB:VT6. It indicates that the period value and changes are available, sourced from FactSet Research Systems Inc. and ICE Data Services.
Price to sales forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
The article focuses on the "Price to sales forward" metric for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It serves as a brief financial data point for the company, indicating a specific period, value, and change percentage for this metric. The content itself seems to be a snapshot from a financial analysis platform like TradingView.
Price to sales forward of Voyager Therapeutics, Inc. – FWB:VT6
This article displays the "Price to sales forward" metric for Voyager Therapeutics, Inc. (FWB:VT6). It includes a table showing the period, value, change, and percentage change for this financial metric. The content itself provides financial data within the TradingView platform.
Voyager’s Alzheimer’s gene therapy gets a late-breaking AAIC poster
Voyager Therapeutics will present a late-breaking poster on its investigational gene therapy, VY1706, for Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) in London, July 12–15, 2026. This announcement follows the recent FDA IND clearance for VY1706, which will allow for a clinical trial in adults with early Alzheimer's, with patient dosing anticipated in the second half of 2026. The poster will detail the IND-enabling GLP non-human primate study of VY1706, a BBB-crossing AAV gene therapy targeting tau.
